By comparing N-glycosylation alterations between high- and low-glutamine pancreatic cancers in clinical specimens using label-free quantitative proteomics, cancer-related pathways, including PI3K-Akt signaling, ECM-receptor interaction, and cell adhesion, were identified (Fig. 5C, D). This evidence concerns the gene AKT1 and familial pancreatic carcinoma.